View More View Less
  • 1 Semmelweis Egyetem, Budapest
  • 2 Semmelweis Egyetem, Budapest
  • 3 Egyesített Szent István és Szent László Kórház, Budapest, Albert Flórián út 5–7. 11/4A, 1097
  • 4 Egyesített Szent István és Szent László Kórház, Budapest
Open access

Absztrakt:

Az őssejt-transzplantációhoz társult thromboticus microangiopathia egy multifaktoriális szövődmény transzplantáció után. Incidenciája a különböző diagnosztikus kritériumrendszerek miatt nagyon eltérő az irodalomban. A thromboticus microangiopathia aktivitását jelző klinikai paraméterek, így a laktátdehidrogenáz-emelkedés, a hematológiai paraméterek és a vesefunkció változásai az őssejt-transzplantáció után nem specifikusak. A patomechanizmusában a klasszikus és az alternatív út diszregulációjának egyaránt szerepe lehet, azonban a komplex patomechanizmus pontosan még nem ismert. A jövőben a komplement paraméterek, köztük a terminális komplement út aktivációs komplex monitorozása segítheti a klinikusokat a gyors és pontos diagnózisban, a kezelésre szoruló betegek optimális kiválasztásában, a terápia várható hatékonyságának előrejelzésében és eredményességének monitorizálásában. A közlemény a thromboticus microangiopathia diagnosztikus kritériumrendszereinek és a terápiás lehetőségeinek változásait, valamint a hazai gyermek betegekben szerzett tapasztalatokat mutatja be. Orv Hetil. 2017; 158(27): 1043–1050.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339: 1578–1584.

  • 2

    Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015; 29: 191–204.

  • 3

    Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016; 31: 15–39.

  • 4

    Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. 1925. Mt Sinai J Med. 2003; 70: 352–355.

  • 5

    Franchini M. Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clin Chem Lab Med. 2015; 53: 1679–1688.

  • 6

    Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6: 60.

  • 7

    Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015; 35: 421–447.

  • 8

    Besbas N, Karpman D, Landau D, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006; 70: 423–431.

  • 9

    Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2014; 29: 148–167.

  • 10

    Grisaru S. Management of hemolytic-uremic syndrome in children. Int J Nephrol Renovasc Dis. 2014; 7: 231–239.

  • 11

    Obut F, Kasinath V, Abdi R. Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant. 2016; 51: 891–897.

  • 12

    Jodele S, Dandoy CE, Myers KC, et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci. 2016; 54: 181–190.

  • 13

    Jodele S, Zhang K, Zou F, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016; 127: 989–996.

  • 14

    Uderzo C, Bonanomi S, Busca A, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82; 638–644.

  • 15

    Cho BS, Yahng SA, Lee SE, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010; 90: 918–926.

  • 16

    Laskin BL, Goebel J, Davies SM, et al. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118: 1452–1462.

  • 17

    Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11: 571–575.

  • 18

    Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100.

  • 19

    García-Martin P, Alarcón-Payer C, López-Fernández E, et al. Transplantation-associated thrombotic microangiopathy in patients treated with sirolimus and cyclosporine as salvage therapy for graft-versus-host disease. Ann Pharmacother. 2015; 49: 986–994.

  • 20

    Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124: 645–653.

  • 21

    Mannucci PM, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thromb Res. 2015; 136: 851–854.

  • 22

    Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122: 2003–2007.

  • 23

    Rosenthal J. Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. J Blood Med. 2016; 7: 181–186.

  • 24

    Holbro A, Passweg JR. Management of hemolytic anemia following allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program 2015; 2015: 378–384.

  • 25

    Didsbury MS, Mackie FE, Kennedy SE. A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients. Pediatr Transplant. 2015; 19: 460–470.

  • 26

    Ganapathi L, Arnold A, Jones S, et al. Use of cidofovir in pediatric patients with adenovirus infection. Version 1. F1000Res. 2016; 5: 758.

  • 27

    Yamada-Fujiwara M, Miyamura K, Fujiwara T, et al. Diagnosis of intestinal graft-versus-host disease and thrombotic microangiopathy after allogeneic stem cell transplantation. Tohoku J Exp Med. 2012; 227: 31–37.

  • 28

    El-Bietar J, Warren M, Dandoy C, et al. Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015; 21: 1994–2001.

  • 29

    Kim SS, Patel M, Yum K, et al. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion 2015; 55: 452–458.

  • 30

    Sarode R, McFarland JG, Flomenberg N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995; 16: 271–275.

  • 31

    Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368: 2169–2181.

  • 32

    Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014; 20: 518–525.

  • 33

    Jodele S, Fukuda T, Mizuno K, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016; 22: 307–315.

  • 34

    Verbiest A, Pirenne J, Dierickx D. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev. 2014; 28: 269–279.

  • 35

    Shochet L, Kanellis J, Simpson I, et al. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. Nephrology 2017; 22(Suppl 1): 23–27.

  • 36

    Gavriilaki E, Sakellari I, Anagnostopoulos A, et al. Transplant-associated thrombotic microangiopathy: opening Pandora’s box. Bone Marrow Transplant. 2017 Mar 13. [Epub ahead of print]

    • Crossref
    • Export Citation
  • 37

    Yeates L, Slatter MA, Bonanomi S, et al. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2017; 52: 762–764.

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

Mendeley citation style is available HERE.

 

MANUSCRIPT SUBMISSION

  • Impact Factor (2018): 0.564
  • Medicine (miscellaneous) SJR Quartile Score (2018): Q3
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu